X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Alzheimers Medicine Change Helped Biden Win Medicare Costs

Content Team by Content Team
30th September 2022
in FDA Approvals, News

Despite the fact that the decision to severely restrict coverage of an expensive new Alzheimer’s medicine, U.S. President Joe Biden celebrated success on September 27th by claiming that expenditures for tens of millions of Americans enrolled in the Medicare health programme had decreased.

For the first time in more than ten years, Medicare Part B premiums will decrease starting in 2019, according to Biden. This programme covers, among other things, doctor and hospital visits as well as the medications physicians prescribe. According to him, each beneficiary will save more than $60 per year as a result.

At a White House Rose Garden event, Biden told healthcare activists, it’s going to be a blessing for many families.

Some of this will require some time to take effect, but it is locked in, he said. About 35 million Americans aged 65 or older or who are disabled are covered by the government’s Medicare programme. Over 29 million people receive benefits from commercial insurers through Medicare Advantage programmes separately.

The lower rates, according to Biden, are a result of his and other Democratic lawmakers’ efforts to slash healthcare costs and inflation for senior citizens, an important voting constituency in the forthcoming midterm Congressional races in November.

The primary reason for the decline, according to the Centers for Medicare and Medicaid Services (CMS), which manages the Medicare insurance plan, is that it only covers individuals enrolled in clinical trials for the Alzheimer’s medicine Aduhelm, made by Biogen Inc.

A contingency margin was built into the 2022 premium to pay for anticipated Part B spending on the brand-new medication Aduhelm. Larger reserves were created as a result of lower-than-anticipated spending on both Aduhelm and other Part B goods and services, the agency stated.

According to CMS, the average monthly premium for Medicare Part B users will be $164.90 in 2023, a $5.20 decrease from 2022. However, the agency has increased 2022 premiums by 14.5%, partly due to anticipated costs for Aduhelm. Prior estimates, premiums for 2022 would have been $160.30 if the medicine had been completely excluded. Therefore, the 2023 rates of 164.90 would have truly represented an increase of 2.8%.

The Food and Drug Administration’s outside advisors, who did not think the drug’s patient benefits were conclusively demonstrated by data, objected to Aduhelm’s approval. The use of Biogen medicine has been significantly constrained as a result of Medicare’s coverage restrictions.

Previous Post

Testing Expert: Omicron Infection Protects Against Influenza

Next Post

Japan Approves Daiichi Sankyo Blood Cancer Drug Ezharmia

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Drug Development

Global Biopharma Market to Hit $566B by 2032

7th March 2025
Next Post

Japan Approves Daiichi Sankyo Blood Cancer Drug Ezharmia

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In